Wet Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EU authorizes Rimmyrah (ranibizumab) from Qilu Pharma Spain S.L. for indications including wet age-related macular degeneration, macular ede…
-
EMA approval · 2026-08-18EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH
The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this a…
-
EMA approval · 2026-08-03EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
EMA authorises Vabysmo (faricimab) for wet macular degeneration, macular edema, and diabetes-related eye complications.
-
EMA approval · 2026-08-03EMA Authorised: Lytenava (bevacizumab) — Outlook Therapeutics NL B. V.
EMA authorised Lytenava (bevacizumab) for wet age-related macular degeneration, marking an approved product from Outlook Therapeutics NL B. …
-
CLINICAL_TRIALS trial_result · 2026-08-03Clinical Trial Results: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 clinical trial results evaluating the efficacy and safety of ONS-5010 in subjects with neovascular age-related macular degeneration.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
Phase 3 trial assessing the safety of ONS-5010 in subjects with visual impairment due to retinal disorders completed with results posted.
-
EMA approval · 2026-07-03EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
Aflibercept-based therapy Opuviz has been authorised in the EU for multiple ocular conditions including wet age-related macular degeneration…
-
EMA approval · 2026-07-03EMA Authorised: Rexatilux (ranibizumab) — Intas Third Party Sales 2005 S.L.
Authorisation of Rexatilux (ranibizumab) by EMA for wet age-related macular degeneration.
-
EMA approval · 2026-07-01EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and…
-
CLINICAL_TRIALS trial_result · 2026-06-30Clinical Trial Results: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial results for ONS-5010 in neovascular age-related macular degeneration completed with posted results.
-
EMA approval · 2026-06-16EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) by Celltrion Healthcare Hungary Kft. for multiple retinal diseases including wet age-related macular …
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial evaluating the efficacy and safety of ONS-5010 in neovascular age-related macular degeneration has completed.
-
EMA approval · 2024-03-26EMA Authorised: Ximluci (ranibizumab) — STADA Arzneimittel AG
European Medicines Agency authorised Ximluci (ranibizumab) for indications including wet age-related macular degeneration, macular edema, an…
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration [Phase 3]
Phase 3 trial evaluating aflibercept after ranibizumab in exudative age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) [Phase 2]
Phase 2 open-label study of intravitreal ICON-1 in choroidal neovascularization due to age-related macular degeneration has been terminated …
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Ziv-aflibercept Efficacy in Better Regulating AMD [Phase 2]
Phase 2 trial update on ziv-aflibercept for wet macular degeneration shows efficacy signals in regulating disease.
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD [Phase 3]
Phase 3 trial update reporting on safety and ECG data collection for brolucizumab 6 mg intravitreal treatment in wet age-related macular deg…
-
CLINICAL_TRIALS trial_result · 2020-06-19Clinical Trial Update: Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating dorzolamide-timolol in combination with anti-VEGF injections for neovascular/wet age-related mac…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME. [Phase 2]
Phase 2 trial evaluating dorzolamide-timolol drops administered with injections for wet AMD, age-related macular degeneration, diabetic macu…
-
CLINICAL_TRIALS trial_result · 2018-11-30Clinical Trial Update: Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy [Phase 4]
Phase 4 trial comparing intravitreal ranibizumab with triamcinolone acetonide (TA) combination therapy versus ranibizumab alone for polypoid…